Local Pro- and Anti-Coagulation Therapy in the Plastic Surgical Patient: A Literature Review of the Evidence and Clinical Applications
Jeremie D. Oliver,
Emma P. DeLoughery,
Nikita Gupta,
Daniel Boczar,
Andrea Sisti,
Maria T. Huayllani,
David J. Restrepo,
Michael S. Hu,
Antonio J. Forte
Affiliations
Jeremie D. Oliver
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN 55905, and Scottsdale, AZ 85259, USA
Emma P. DeLoughery
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN 55905, and Scottsdale, AZ 85259, USA
Nikita Gupta
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN 55905, and Scottsdale, AZ 85259, USA
Daniel Boczar
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL 32224, USA
Andrea Sisti
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL 32224, USA
Maria T. Huayllani
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL 32224, USA
David J. Restrepo
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL 32224, USA
Michael S. Hu
Department of Plastic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Antonio J. Forte
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL 32224, USA
The risks of systemic anti-coagulation or its reversal are well known but accepted as necessary under certain circumstances. However, particularly in the plastic surgical patient, systemic alteration to hemostasis is often unnecessary when local therapy could provide the needed adjustments. The aim of this review was to provide a summarized overview of the clinical applications of topical anti- and pro-coagulant therapy in plastic and reconstructive surgery. While not a robust field as of yet, local tranexamic acid (TXA) has shown promise in achieving hemostasis under various circumstances, hemostats are widely used to halt bleeding, and local anticoagulants such as heparin can improve flap survival. The main challenge to the advancement of local therapy is drug delivery. However, with increasingly promising innovations underway, the field will hopefully expand to the betterment of patient care.